HealthQuill GSK Plc
Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.
Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

Read More
An oral antibiotic, gepotidacin, has shown efficacy in fighting gonorrhoea — one of the most prevalent sexually transmitted infections in the world, according to the results of an end-stage study published in The Lancet.
Drugs Health Research

Oral antibiotic shows efficacy in end-stage trials to treat gonorrhoea

HQ Team April 16, 2025: An oral antibiotic, gepotidacin, has shown efficacy in fighting gonorrhoea — one of the most prevalent sexually transmitted.

Read More
The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in adult women and girls above 12 years, according to the company.
Drugs Medical Pharma

GSK’s drug to fight urinary tract infections gets USFDA approval

HQ Team March 26, 2025: The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in.

Read More
GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug 

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Read More
GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to make sterile liquid vaccines and medicines as demand grows.
Drugs Health Pharma

GSK to invest $800 million in US to double capacity at Marietta facility

GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to.

Read More
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season compared to 94.1% in the first and 64.2% in the second.
Drugs Health Pharma

GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year

GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.

Read More
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.
Drugs Health Pharma

US regulator allows GSK’s endometrial cancer therapy for expanded use

The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.

Read More
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health Pharma

GSK’s blood cancer test drug halves risk of disease progression: Data 

British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.

Read More
The first dosing in a late-stage trial to evaluate an investigational drug for tuberculosis (TB) has started in South Africa, which has one of the highest burdens in the world.
Drugs Health Pharma

First late-stage trial vaccine doses begin in South Africa for tuberculosis

 HQ Team March 20, 2024: The first dosing in a late-stage trial to evaluate an investigational drug for tuberculosis (TB) has started in.

Read More
British drugmaker GSK Plc., will pay $1.4 billion to acquire Anglo-American biopharmaceutical company  Aiolos Bio Inc., which makes medicines to treat asthma.
Drugs Health Pharma

GSK Plc., to buy asthma drugmaker Aiolos Bio for $1.4 billion  

HQ Team January 9, 2023: British drugmaker GSK Plc., will pay $1.4 billion to acquire Anglo-American biopharmaceutical company  Aiolos Bio Inc., which makes.

Read More